BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

CARsgen Therapeutics Administers First Dose of KJ-C2320 Allogeneic CAR T-Cell Therapy in Investigator-Initiated Trial

CARsgen Therapeutics Holdings Limited , a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors...

January 21, 2025 | News

YolTech Therapeutics Launches Clinical Trial for YOLT-204 a First-in-Class Gene Editing Therapy for Beta-Thalassemia

YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the initiation of a clinical trial for Y...

January 21, 2025 | News

Charles River and Akron Bio Advance Cell Therapy Manufacturing with Integration of Closed System Cytokines

Charles River Laboratories International, Inc. (NYSE: CRL) and Akron Bio (“Akron”), a leading supplier of critical materials and services for a...

January 17, 2025 | News

Verismo Therapeutics Secures $4.05M Investment from IFLI to Advance SynKIR™-310 for Follicular Lymphoma

Verismo will receive up to $4.05 million USD in investments from the Institute for Follicular Lymphoma Innovation (IFLI). The partnership with...

January 08, 2025 | News

JCR Pharmaceuticals and Modalis Therapeutics Advance CNS Gene Therapy Collaboration

JCR Pharmaceuticals Co., Ltd. and Modalis Therapeutics Corporation announced that they have validated the initial proof of concept in a jo...

January 06, 2025 | News

Sangamo Therapeutics Regains Rights to Hemophilia A Gene Therapy After Pfizer Ends Collaboration

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it will regain development and commercialization rights to giroctoco...

January 02, 2025 | News

Sensorion Completes Enrollment for First Cohort in Audiogene Phase 1/2 Gene Therapy Trial

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to re...

January 01, 2025 | News

CARsgen Launches Clinical Trial in China for Innovative Allogeneic CAR T Therapy Targeting CD19/CD20

CARsgen Therapeutics Holdings Limited , a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors...

January 01, 2025 | News

CARsgen's Satricabtagene Autoleucel Achieves Positive Phase II Results in Advanced Gastric Cancer

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic mal...

December 31, 2024 | News

I Peace Achieves Milestone of Manufacturing 100 GMP-Grade iPS Cell Lines

Leading GMP cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the n...

December 31, 2024 | News

New Therapeutics Venture GEMMABio Secures $34M in Seed Funding to Accelerate Gene Therapy Initiatives

Significant international investment defies sector trend GEMMA Biotherapeutics ("GEMMABio") – a new therapeutics company founded by gene therapy pio...

December 24, 2024 | News

YolTech Therapeutics Advances YOLT-201 Gene-Editing Therapy to Dose-Expansion Phase in ATTR Amyloidosis Clinical Trial

YolTech Therapeutics announced updated data from its ongoing Phase I/IIa clinical trial of YOLT-201, a first-in-class CRISPR/Cas9-based in vivo gene-editin...

December 23, 2024 | News

SCG Cell Therapy Partners with A*STAR BTI and NATi to Accelerate RNA-Based Therapeutics Development and Commercialization

SCG Cell Therapy signed a Memorandum of Understanding (MoU) with A*STAR Bioprocessing Technology Institute (A*STAR BTI) and Nucleic Acid Therapeutics Ini...

December 23, 2024 | News

PeproMene Bio Secures $11M Investment to Advance BAFF-R CAR T Therapy for Relapsed Follicular Lymphoma

Based on promising early clinical results from PeproMene Bio's PMB-102 Phase 1 study, they will receive $6M USD upfront plus an addit...

December 20, 2024 | News

Stay Connected